Rapid Initiation of Drug Treatment Engagement

PHASE4CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

March 30, 2022

Study Completion Date

June 30, 2023

Conditions
Opioid-use DisorderOverdose
Interventions
DRUG

buprenorphine/naloxone

"A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs"

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Prevention Point Philadelphia

OTHER

collaborator

Public Health Management Corporation

OTHER

collaborator

Philadelphia Department of Public Health

OTHER_GOV

lead

University of Pennsylvania

OTHER

NCT03908437 - Rapid Initiation of Drug Treatment Engagement | Biotech Hunter | Biotech Hunter